1. Home
  2. STIM vs ABOS Comparison

STIM vs ABOS Comparison

Compare STIM & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neuronetics Inc.

STIM

Neuronetics Inc.

N/A

Current Price

$1.32

Market Cap

105.5M

Sector

Health Care

ML Signal

N/A

Logo Acumen Pharmaceuticals Inc.

ABOS

Acumen Pharmaceuticals Inc.

N/A

Current Price

$3.19

Market Cap

155.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
STIM
ABOS
Founded
2003
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
105.5M
155.7M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
STIM
ABOS
Price
$1.32
$3.19
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$7.00
$7.50
AVG Volume (30 Days)
2.2M
297.4K
Earning Date
05-01-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$52,776,000.00
N/A
Revenue This Year
$101.67
N/A
Revenue Next Year
$10.87
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.17
$0.86
52 Week High
$5.34
$3.41

Technical Indicators

Market Signals
Indicator
STIM
ABOS
Relative Strength Index (RSI) 42.63 64.17
Support Level $1.24 $1.21
Resistance Level $2.13 N/A
Average True Range (ATR) 0.11 0.24
MACD 0.01 0.03
Stochastic Oscillator 46.77 74.90

Price Performance

Historical Comparison
STIM
ABOS

About STIM Neuronetics Inc.

Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.

About ABOS Acumen Pharmaceuticals Inc.

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.

Share on Social Networks: